Management ChangeApr 30, 2026, 04:10 PM
RMD CFO Brett Sandercock to Retire; Aaron Bloomer Appointed Successor
AI Summary
ResMed announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026, after 27 years with the company. Aaron Bloomer, formerly CFO of Exact Sciences, has been appointed as his successor. Sandercock will continue to serve as an advisor to the CEO through the end of calendar year 2027. The company also reiterated its fiscal year 2026 outlook, including gross margin, SG&A, R&D, and effective tax rate.
Key Highlights
- Brett Sandercock, CFO, plans to retire effective May 4, 2026, after 27 years with ResMed, including 20 as CFO.
- Aaron Bloomer has been appointed as the new Chief Financial Officer.
- Bloomer joins ResMed from Exact Sciences, where he served as CFO.
- Bloomer brings over 17 years of global finance and operating leadership experience.
- Sandercock will serve as an advisor to the CEO through the end of calendar year 2027.
- ResMed reiterated its fiscal year 2026 outlook, including gross margin of 62-63%.
- SG&A expenses are projected in the range of 19-20% for FY2026.
- R&D expenses are expected in the range of 6-7% and effective tax rate 21-23% for FY2026.
Price Impact
More from RMD